CombiGene´s lead project CG01 has received funding from the European Union´s Horizon 2020 research and innovation programme

Intensive science summer

Jun 26, 2019

Esbjörn Melin, researcher and doctoral student at the Epilepsy Centre, Lund University Faculty of Medicine, looks forward to a busy summer. Much of the research behind CombiGene’s CG01epilepsy project has been conducted at the Epilepsy Centre, Lund University Faculty of Medicine. This work includes the successful proof-of-concept study which Esbjörn presented at the13th European Congress on Epileptology in Vienna, Austria.

This summer, Esbjörn will particpate in two major international conferences. The first is the 33rd International Epilepsy Conference in Bangkok (22-26 June), where Esbjörn will give a poster presentation. The Bangkok conference, held every other year, is one of the most important conferences for global epilepsy research

The other conference is the 12th International NPY-PYY-PP Gairdner International Symposium (27-31 July) in Canada, to which Esbjörn has been invited to present the NPY/Y2 study, the science that is the very core of CombiGene’s candidate drug, CG01. Esbjörn will also give a poster presentation at this conference.